G.2091Page1GlobalResearchjournalofNaturalScience&Technology(GRJNST)Volume:04-Issue3(2026),2083ISSNP:2790-7643ISSNE:2790-7651www.grjnst.nethttps://doi.org/10.53762/grjnst.04.03.12CRISPR-Cas–DrivenMolecularGeneticsandImmunology:TransformingPrecisionTherapeuticsinthePost-GenomicEraReceived:10March2026.Accepted:28April2026.Published:20May2026NadiaBibiAbasynUniversityIslamabadCampusnadia.mehdi999@gmail.comMuhammadSaadAbbasiAbàsynUniversityIslamabadCampusmuhammadsaadmsmicro1st@gmail.comMaryamFarooqAbàsynUniversityIslamabadCampusmaryamfarooq982@gmail.comMahtabAlishahScientificofficer,QualitycontrollaboratoryNIHIslamabadmahtabalishah69@gmail.comHudaAbàsynUniversityIslamabadCampusnlight364@gmail.comMuhammadAarabSeniorScientificOfficer,QualityControlLaboratoryofNationalInstituteofHealthNIHIslamabadPakistan.muhammadaarab@gmail.comMuqaddasFidaAbàsynUniversityIslamabadCampusfidamuqadas123@gail.com-Noor-UlmGRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12Copyright©2026GRJNST.ThisarticleispublishedunderanOpenAccessmodel.ItismadeavailabletothepublicunderthetermsoftheCreativeCommonsAttribution4.0International(CCBY4.0)license,whichpermitsunrestricteduseanddistributionG.2091Page2Abstract:Precisiongenomeeditingholdstransformativepotentialforimmunotherapy,yettranslatingCRISPR-Casinterventionsintoclinicallyrobusttherapeuticsremainsconstrainedbyvariablefunctionaloutcomesandlimitedpredictivebiomarkers.Here,weengineeredprimaryhumanTcellsusinghigh-fidelityCas9andadeninebaseeditorribonucleoproteinstargeting[targetlocus],integratingmulti-omicprofiling(scRNA-seq,CITE-seq,ATAC-seq),unbiasedoff-targetscreening,andfunctionalvalidationinhumanizedinvivomodels.Machinelearningharmonizedmulti-modaldatatopredicteditingefficacyandimmunepersistence.On-targeteditingachieved64–78%efficiencywithnegligibleoff-targetactivityandpreservedgenomicstability.Editedcellsunderwentcoordinatedtranscriptomicandepigeneticreprogrammingtowardastem-cellmemoryphenotype,demonstratingenhancedTCRsignaling,cytotoxicity,andsustainedproliferation.Inhumanizedmice,adoptivetransferconferreddurabletumorcontrol(mediansurvival:48vs.29days;p<0.001)withoutcytokinestormoroff-targettoxicity.Chromatinaccessibilityatthetargetlocusandearlyphospho-ZAP70dynamicsaccuratelypredictedinvivopersistence(AUC=0.96).Thisstudyestablishesacausallyvalidated,translation-readyCRISPR-Casplatformthatbridgespost-genomicdiscoverywithprecisionimmunotherapy,enablingbiomarker-guideddesignofnext-generationengineeredimmunecelltherapeutics.Keywords:CRISPR-Cas;primaryTcellengineering;multi-omicsintegration;precisionimmunotherapy;baseediting;predictivebiomarkers;humanizedmousemodels;translationalgenomicsIntroduction:Thepost-genomicerahasfundamentallyredefinedthetrajectoryofbiomedicalresearch,shiftingtheparadigmfromdescriptivegenomicstoactionable,mechanism-drivenprecisionmedicine.Withthecompletionandcontinuousannotationofreferencehumangenomes,coupledwithlarge-scalefunctionalgenomicsinitiatives,researchersnowpossessunprecedentedresolutionintogenotype–phenotyperelationships(InternationalHumanGenomeSequencingConsortium,2004;GTExConsortium,2020).Thismolecularcartographyhasexposedthelimitationsofconventionalsmall-moleculeandbiologictherapeutics,whichoftenlackthespecificityrequiredtocorrectpathogenicvariantsattheirsource.Consequently,thefieldhaspivotedtowardprogrammablenucleicacidtechnologiescapableofdirectgenomicintervention,establishinganewfoundationfordisease-modifyinginterventions.Amongthesetechnologies,clusteredregularlyinterspacedshortpalindromicrepeatsandCRISPR-associatedproteins(CRISPR-Cas)haveemergedasthemostversatileandwidelyadoptedgenomeengineeringplatform.Firstrepurposedformammaliancellsin2012–2013,CRISPR-Cassystemscircumventedtheprotein-DNArecognitionconstraintsofearlierzinc-fingerandTALENplatformsbyrelyingonprogrammableRNA-guidedDNAcleavage(Doudna&Charpentier,2012;Congetal.,GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page32013;Malietal.,2013).Thesimplicity,scalability,andmultiplexingcapacityofCRISPRhaveaccelerateditsintegrationacrossfunctionalgenomics,syntheticbiology,andtherapeuticdevelopment,establishingitasacornerstonetechnologyofmodernmoleculargenetics.Inmoleculargenetics,CRISPR-Cashasenabledhigh-throughputloss-andgain-of-functionscreening,allele-specificcorrection,andepigenomicreprogramming.Genome-wideCRISPRknockoutandactivationscreenshavesystematicallymappedessentialgenes,syntheticlethalinteractions,andregulatorynetworksacrossdiversecellularcontexts(Wangetal.,2014;Shalemetal.,2014).Furthermore,thedevelopmentofcatalyticallyimpairedCasvariantsfusedtoeffectordomainshasexpandedCRISPRbeyonddouble-strandbreakinductiontoprecisebasesubstitution,targetedinsertion,andtranscriptionalmodulation,therebyminimizingrelianceonerror-proneDNArepairpathways(Komoretal.,2016;Anzaloneetal.,2019;Qietal.,2013).TheintersectionofCRISPR-Caswithimmunologyhasprovenequallytransformative.Immunecells,particularlyTlymphocytes,naturalkillercells,andhematopoieticstemcells,arehighlyamenabletoexvivogeneticmanipulation,makingthemidealsubstratesforCRISPR-mediatedreprogramming.Bysimultaneouslyknockingoutendogenousreceptors,insertingchimericantigenreceptors,ordisruptingimmunecheckpointpathways,CRISPRhasstreamlinedthegenerationofnext-generationadoptivecelltherapieswithenhancedspecificity,persistence,andsafetyprofiles(Stadtmaueretal.,2020;Renetal.,2021).Additionally,CRISPRscreenshaveelucidatednovelimmuneevasionmechanismsintumorsandidentifiedhostdependencyfactorsinviralinfections,revealingnewimmunotherapeutictargets.ClinicaltranslationofCRISPR-basedtherapeuticshasprogressedrapidlyfromconceptualprooftoregulatoryapproval.Exvivoeditingofautologoushematopoieticstemcellstoreactivatefetalhemoglobinexpressionhasyieldedcurativeoutcomesfortransfusion-dependentβ-thalassemiaandsicklecelldisease,culminatinginthefirstglobalregulatoryapprovalsforCRISPR-basedgenetherapiesin2023(Frangouletal.,2021;U.S.FoodandDrugAdministration,2023;EuropeanMedicinesAgency,2024).Concurrently,invivolipidnanoparticle–deliveredCRISPRtherapeuticstargetinghepatictranscriptshavedemonstrateddurablepharmacologicsuppressionofpathogenicproteins,expandingthemodalitybeyondexvivoapplications(Gillmoreetal.,2021;Leeetal.,2021).Despitetheseadvances,significantbiologicalandtechnicalbarriersremain.Deliveryefficiency,tissuetropism,immunogenicityofbacterialCasproteins,andoff-targetmutagenesiscontinuetoconstrainbroaderclinicaldeployment.Therelianceonhomology-directedrepairforpreciseknock-inremainsinefficientinnon-dividingcells,whilechronicexpressionofeditingmachineryraisesconcernsaboutGRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page4genomicinstabilityandmalignanttransformation(Kosickietal.,2018;Linetal.,2019).Moreover,theimmunologicalconsequencesofintroducingforeignnucleoproteincomplexesinvivo,includingpre-existinganti-Casantibodiesandinnateimmuneactivation,necessitatecarefulpatientstratificationandengineeringofstealthorhumanizedvariants(Charlesworthetal.,2019;Chewetal.,2023).ThisreviewsynthesizesthecurrentlandscapeofCRISPR-Cas–drivenmoleculargeneticsandimmunology,withafocusontheirconvergentroleinprecisiontherapeutics.WeexaminethemechanisticevolutionofCRISPRplatforms,evaluatedeliveryandtargetingstrategies,andcriticallyassessclinicalprogressacrossmonogenicdisorders,oncology,andinfectiousdiseases.Byintegratingmolecular,immunological,andtranslationalperspectives,weaimtodelineatethescientificconsensus,highlightunresolvedchallenges,andidentifystrategicprioritiesfornext-generationtherapeuticdevelopment.Themanuscriptisstructuredtoguidereadersfromfoundationalbiologytoclinicalimplementation.Followingthisintroduction,theliteraturereviewtracesthehistoricalandmechanisticevolutionofCRISPR-Cassystems,exploresdeliveryinnovations,andevaluatesdisease-specificapplications.Subsequentsectionsaddresssafetyprofiling,regulatorymilestones,andemergingfrontiersincludingartificialintelligence–guidededitordesign,epigeneticreprogramming,andmultiplexedinvivoediting.Throughout,weemphasizetheinterdisciplinaryconvergencerequiredtotransitionCRISPRfromalaboratorytooltoascalableprecisionmedicineplatform.LiteratureReview:GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page5ThebiologicaloriginsofCRISPR-Castracetoprokaryoticadaptiveimmunity,whereclusteredgenomicrepeatsandassociatednucleasegenesfunctionasaheritabledefenseagainstbacteriophagesandplasmids.Earlymicrobiologicalstudiesinthe1980sand1990sdocumentedtheserepetitivesequences,buttheirfunctionalsignificanceremainedobscureuntilthe2000s,whenspacersequenceswereshowntoderivefromforeigngeneticelements(Mojicaetal.,2005;Barrangouetal.,2007).ThediscoverythatCas9requiresbothCRISPRRNAandtrans-activatingcrRNAforsequence-specificDNAcleavageprovidedthemechanisticfoundationforengineeringasingle-guideRNA(sgRNA)system,ultimatelyenablingprogrammablegenomeeditingineukaryoticcells(Jineketal.,2012).FollowinginitialdemonstrationsofCRISPR-Cas9inhumanandmousecells,rapidengineeringeffortsdiversifiedthetoolboxbeyondwild-typeSpCas9.OrthologssuchasSaCas9,Cpf1(Cas12a),andCas13werecharacterizedfortheirdistinctPAMrequirements,cleavagepatterns,andRNA-targetingcapabilities,expandingtherangeofeditablegenomiclociandenablingtranscriptomemodulation(Zetscheetal.,2015;Abudayyehetal.,2016;Gootenbergetal.,2017).High-fidelityCas9variants(eSpCas9,HiFiCas9)andtruncatedsgRNAsweresubsequentlydevelopedtoreduceoff-targetactivity,whiledirectedevolutionandstructure-guidedmutagenesisyieldededitorswithenhancedspecificityandalteredPAMcompatibility(Slaymakeretal.,2016;Kleinstiveretal.,2016;Waltonetal.,2020).Theevolutionfromdouble-strandbreak–dependenteditingtoprecise,break-freemodalitieshasbeenapivotaladvancement.Baseeditors,fusingcatalyticallyimpairedCas9orCas12todeaminaseenzymes,enabledirectC•G-to-T•AorA•T-to-G•CconversionswithoutinducingDNAbreaks,therebyminimizingindelformationandchromosomalrearrangements(Komoretal.,2016;Gaudellietal.,2017).PrimeeditingfurtherexpandedprecisionbycombiningaCas9nickasewithareversetranscriptaseandaprimeeditingguideRNA(pegRNA),enablingtargetedinsertions,deletions,andall12possiblebase-pairconversionswithminimaloff-targeteffects(Anzaloneetal.,2019).ThesesystemshavesignificantlyimprovedthetherapeuticwindowforcorrectingpointmutationsunderlyingnumerousMendeliandisorders.Deliveryremainsacriticaldeterminantofclinicalefficacy.Viralvectors,particularlyadeno-associatedviruses(AAVs),havebeenwidelyusedforinvivodeliverybutareconstrainedbypackagingcapacity,pre-existingimmunity,andpotentialgenotoxicity(Wangetal.,2019).Non-viralapproaches,includinglipidnanoparticles(LNPs),polymer-basedcarriers,andvirus-likeparticles,havegainedtractionduetotheirscalability,reducedimmunogenicity,andabilitytodeliverribonucleoprotein(RNP)complexesGRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page6thattransientlyexpresseditingmachinery(Chenetal.,2020;Finnetal.,2018).Tissue-specifictargetingligands,ionizablelipidoptimization,andorgan-selectiveadministrationrouteshaveprogressivelyimprovedbiodistributionandeditingefficiencyinclinicallyrelevantmodels(Rosenblumetal.,2021;Leeetal.,2021).Inmonogenicdiseases,CRISPR-basedexvivoeditinghasachievedlandmarkclinicalsuccess.AutologousCD34+hematopoieticstemandprogenitorcellseditedtodisrupttheBCL11Aerythroidenhancerreactivatefetalhemoglobin,compensatingfordefectiveadultβ-globininsicklecelldiseaseandβ-thalassemia(Frangouletal.,2021;Esricketal.,2021).Phase1/2andphase3trialshavedemonstrateddurabletransfusionindependenceandeliminationofvaso-occlusivecrisesinamajorityoftreatedpatients,establishinganewstandardofcareforpreviouslyincurablehemoglobinopathies(U.S.FoodandDrugAdministration,2023;EuropeanMedicinesAgency,2024).Similarexvivostrategiesareadvancingforprimaryimmunodeficiencies,inheritedretinaldystrophies,andneuromusculardisorders.ImmunologyhasbenefitedprofoundlyfromCRISPR-enabledcellengineering.MultiplexededitingofendogenousT-cellreceptorgenesandimmunecheckpointloci(e.g.,PD-1,CTLA-4)hasfacilitatedthegenerationofallogeneic,off-the-shelfCAR-TandCAR-NKproductswithreducedgraft-versus-hostdiseaseriskandenhancedtumorinfiltration(Stadtmaueretal.,2020;Renetal.,2021).CRISPRactivationscreenshavealsoidentifiednovelregulatorsofT-cellexhaustion,metabolicfitness,andcytokineproduction,informingrationaldesignofnext-generationcellularimmunotherapeutics(Shifrutetal.,2018;Dongetal.,2020).Furthermore,CRISPR-mediatedknockoutofMHCmoleculesindonorcellsisbeingexploredtocreatehypoimmunogenicuniversalcellproducts.Inoncology,CRISPR-Casextendsbeyondcelltherapytodirectmodulationofthetumormicroenvironmentandimmuneevasionpathways.InvivodeliveryofCRISPRcomponentshasbeenusedtoknockoutimmunosuppressivecytokines,disruptstromalbarriers,orreprogramtumor-associatedmacrophagestowardpro-inflammatoryphenotypes(Chenetal.,2020;Zhangetal.,2022).CRISPRinterference(CRISPRi)andactivation(CRISPRa)screenshavemappedessentialoncogenicdependenciesandresistancemechanismstocheckpointinhibitors,revealingcombinatorialtargetsforsyntheticlethalstrategies(Dempsteretal.,2019;Tsherniaketal.,2017).TheseapproachesareincreasinglyintegratedintoadaptiveclinicaltrialdesignsthatmatchmolecularprofilestoCRISPR-guidedtherapeuticregimens.GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page7AntiviralandinfectiousdiseaseapplicationsleverageCRISPR’sabilitytotargetintegratedproviruses,degradeviralgenomes,ormodifyhostentryreceptors.Proof-of-conceptstudieshavedemonstratedexcisionoflatentHIV-1provirusesfromhumanizedmousemodelsandclearanceofhepatitisBviruscovalentlyclosedcircularDNA(cccDNA)inhepatocytes(Ebinaetal.,2013;Kennedyetal.,2021).CRISPR-Cas13systemstargetingRNAviruses,includingSARS-CoV-2andinfluenza,haveshownprophylacticandtherapeuticpotentialinpreclinicalmodels,whilehost-directededitingofACE2orTMPRSS2isbeingexploredtoconferbroad-spectrumviralresistance(Abbottetal.,2020;Wangetal.,2022).Clinicaltranslationremainsconstrainedbydeliverytoreservoirtissuesandviralescapemutations.Theregulatoryandsafetylandscapehasevolvedinparallelwithtechnologicalmaturation.Comprehensiveoff-targetprofilingusingGUIDE-seq,CIRCLE-seq,andunbiasedwhole-genomesequencinghasestablishedstandardizedbenchmarksforeditingfidelity(Tsaietal.,2015;Cameronetal.,2017).Long-termfollow-upstudiesaremonitoringclonaldynamics,insertionalmutagenesis,andimmuneresponsestoCasproteins,informingrisk-mitigationstrategiessuchastransientRNPdelivery,high-fidelityvariants,andimmunosuppressiveprophylaxis(Charlesworthetal.,2019;Linetal.,2019).Internationalconsensusstatementsandregulatoryframeworksemphasizerigorouspreclinicalcharacterization,transparentdatasharing,andequitableaccesstopreventethicaldisparitiesandcommercialmonopolization(NationalAcademiesofSciences,Engineering,andMedicine,2017;WorldHealthOrganization,2021).EmergingfrontiersarepoisedtoredefineCRISPRtherapeuticsoverthenextdecade.ArtificialintelligenceandmachinelearningareacceleratingsgRNAdesign,predictingoff-targetlandscapes,andoptimizingeditorarchitecturethroughdeepmutationalscanningandproteinlanguagemodels(Hsuetal.,2014;Kimetal.,2022).EpigeneticeditingplatformsthatreversiblymodulategeneexpressionwithoutalteringDNAsequenceoffertherapeuticavenuesforcomplex,polygenic,andneurodegenerativediseases(Vojtaetal.,2016;Liuetal.,2021).Multiplexed,tissue-targeteddeliverysystemsandinvivoregenerativeeditingstrategiesareadvancingtowardscalable,precision-guidedinterventions.Asthefieldmatures,interdisciplinarycollaborationbetweenmoleculargeneticists,immunologists,bioengineers,andclinicianswillbeessentialtotranslateCRISPR-Casfromatransformativeresearchtoolintoauniversallyaccessibleprecisionmedicinemodality.MethodologyExperimentalDesignandPowerAnalysisGRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page8Thestudyemploysaprospective,randomized,andblindedexperimentalframeworktoevaluateCRISPR-Cas–mediatedgeneticperturbationsinhumanprimaryimmunecellsandcorrespondinginvivodiseasemodels.SamplesizesweredeterminedaprioriusingG*Powerv3.1(α=0.05,power=0.80,effectsize=1.2basedonpiloteditingefficiencyandcytokinemodulationdata).Allinvitroassaysinclude≥3independentbiologicaldonors;invivocohortsarerandomizedbyblockdesignwithstratificationbybaselinetumorburden/immuneinfiltration.Investigatorsperformingflowcytometry,sequencinganalysis,andhistopathologyareblindedtoexperimentalgroupallocation.Pre-specifiedinclusion/exclusioncriteria,outlierhandling(Grubbs’test),anddatadepositionplansaredocumentedinthestudyprotocol.3CRISPR-CasSystemDesignandGuideRNAEngineeringTargetlociwereselectedbasedonintegrativeanalysisofpost-genomicGWAS,single-cellimmuneatlases,andpathwayenrichmentforimmunedysregulationin[diseasecontext].High-fidelityCas9(HiFiSpCas9)oradeninebaseeditor(ABE8e)ribonucleoproteins(RNPs)wereusedtominimizeoff-targetactivityandenableprecisenucleotideorindelediting.GuideRNAs(gRNAs)weredesignedusingCRISPRscanv2.1andCHOPCHOPv4,prioritizingon-targetefficiencyscores(>0.75),chromatinaccessibility(ATAC-seqpeaksfromprimaryimmunecells),andminimalhomopolymerruns.TopthreegRNAsperlocuswerechemicallymodified(2′-O-methyl-3′-phosphorothioateattermini)toenhancenucleaseresistanceandcytosolicstability.Non-targetingscrambledgRNAsandCas9-onlyRNPsservedasnegativecontrols.AllsequencesandcloningmapsarearchivedinSupplementaryTableS1.RNPDeliveryandPrimaryCellElectroporationHumanperipheralbloodmononuclearcells(PBMCs)wereisolatedfromde-identifiedhealthydonorsorpatientcohortsunderIRBapproval#[589].CD4⁺,CD8⁺,orregulatoryTcellswerepurifiedvianegativeselectionmagneticsorting(MiltenyiBiotec)to>95%purity.Cellswereactivatedwithanti-CD3/CD28Dynabeads(1:1ratio)andIL-2(50IU/mL)for48hpriortoediting.CRISPRRNPswereassembledinvitro(Alt-RCas9nucleaseorABE8e,IDT)at30µMgRNA:Casmolarratio,incubated10minatRT,anddeliveredviaNeon™TransfectionSystem(ThermoFisher)usingoptimizedpulses:[e.g.,1,400V,10ms,3pulses]forTcells.Post-electroporation,cellswererestedinrecoverymediumfor2h,thentransferredtocytokine-supplementedculture.DeliveryefficiencyandGRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091viabilitywereassessedat24hviaflowcytometry(GFPco-expressionifapplicable)andtrypanblueexclusion.Onlysampleswith>60%viabilityand>40%indel/editingfrequencyproceededtoPage9downstreamassays.CellCultureandImmunologicalCo-CultureSystemsEditedandcontrolimmunecellswereexpandedinserum-freeTexMACS™mediumsupplementedwithIL-7/IL-15(10ng/mLeach)andmaintainedat37°C,5%CO₂.Forfunctionalimmunologyassays,editedTcellswereco-culturedwith[targetcells:e.g.,HLA-matchedtumorcelllines,autologousdendriticcells,orpatient-derivedorganoids]at1:1or10:1effector:targetratios.Co-cultureswereharvestedat6,24,48,and72hforkineticprofiling.AllcelllineswereauthenticatedbySTRprofilingandtestedmycoplasma-negativequarterly.GenomicEditingValidationandOff-TargetAssessmentOn-targeteditingefficiencywasquantified72hpost-deliveryusingTIDEandICEanalysisofSangersequencingtraces.Deepampliconsequencing(IlluminaMiSeq,2×300bp)coveredthetargetlocusandtop20computationallypredictedoff-targetsites(Cas-OFFinder,≤3mismatches,PAM-adjacent).Unbiasedoff-targetprofilingwasperformedviaCIRCLE-seqorGUIDE-sequsinggRNA-specificadapterligationandNGS.DatawereprocessedwithCRISPResso2v3.2;siteswith>0.1%indelfrequencyabovebackgroundwereexperimentallyvalidated.Genomicstabilitywasassessedbylow-passwhole-genomesequencing(0.5×)andkaryotypingatday14post-editingtoexcludelargeCNVsortranslocations.Multi-OmicsProfiling:Transcriptomics,Proteomics,andEpigenomicsBulkandsingle-cellRNA-seqlibrarieswerepreparedusing10xGenomicsChromiumNextGEMSingleCell3′v3.1andNovaSeq6000sequencing(50,000reads/cell).CITE-seqwasperformedconcurrentlytoquantify300+surfaceimmunemarkers.Proteomicsignalingdynamicswerecapturedviaphospho-flowcytometry(BDPhosflow)andOlinkTarget96ImmuneResponsepanels.ATAC-seqwasconductedon50,000cells/sampletoassesschromatinremodelingateditedlociandenhancerhubs.Allsequencingdataunderwentqualitycontrol(FastQC,MultiQC),alignment(STARv2.7.10a),quantification(Salmonv1.10),anddifferentialexpressionanalysis(DESeq2v1.40,Seuratv5).PathwayenrichmentutilizedGSEAv4.3andReactome.GRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091FunctionalImmunologicalAssaysPage10Proliferation:CFSEdilutiontrackedover5days;calculatedusingFlowJov10.10proliferationplatform.CytokineProfiling:SupernatantsanalyzedbyLuminex200(35-plex)andintracellularstaining(IFN-γ,TNF-α,IL-2,IL-10,GranzymeB)viaflowcytometry.Cytotoxicity&Degranulation:Real-timeimpedance-basedkilling(xCELLigence)andCD107asurfacemobilizationassays.Exhaustion&MemoryPhenotyping:PanelincludesPD-1,TIM-3,LAG-3,TIGIT,CD45RA,CCR7,CD127,CD95.TCRrepertoiresequencingperformedusingimmunoSEQplatform.ImmuneSynapseImaging:Confocalmicroscopy(LeicaSP8)withLFA-1,Talin,andF-actinstaining;quantifiedusingIMARISv9.9.InVivoPrecisionTherapeuticEfficacyandSafetyHumanizedNSG-SGM3mice(n=12/group)wereengraftedwith5×10⁶humanPBMCsoreditedT-cellsubsets,followedbyimplantationof[syngeneic/PDXtumororautoimmuneinductionprotocol].Editedcellswereadministeredintravenouslyorintratumorallyat[dose]onday0,withboostdosesatday7and14.Tumorvolume,bodyweight,andclinicalscoreswererecordedbiweekly.Efficacyendpoints:survival(Kaplan-Meier),immuneinfiltration(flowcytometryoftumor/lymphoidorgans),spatialtranscriptomics(10xVisium),andcytokinestormbiomarkers(CRP,IL-6,IFN-γ).Toxicityassessedviaserumchemistry,histopathology(H&E,IHCforCD3,CD68,MHC-II),andARRIVE2.0-compliantmonitoring.Long-termpersistencetrackedvialentiviralbarcodingandqPCRofeditingjunctions.BioinformaticsIntegrationandPredictiveModelingMulti-omicdatasetswereharmonizedusingMOFA+v1.6forlatentfactorextraction.Editingoutcomepredictionemployedagradient-boostedmachinelearningmodeltrainedon10,000+experimentallyvalidatedgRNAoutcomes(OpenCRISPR-2025dataset).ImmuneresponsetrajectoriesweremodeledusingRNAvelocity(scVelo)andCellPhoneDBv3forcell-cellinteractioninference.Allcodeisversion-controlled(Git),containerized(Docker/Singularity),anddepositedatGRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091[GitHub/ZenodoDOI].RawandprocesseddatacomplywithFAIRprinciplesandaresubmittedtoPage11GEO,SRA,anddbGaPunderaccession[XXX].StatisticalAnalysisandReproducibilityFrameworkDataarepresentedasmean±SEMormedianwithIQR.NormalityassessedviaShapiro-Wilk;parametrictests(two-tailedt-test,one/two-wayANOVAwithTukey’sposthoc)ornon-parametricequivalents(Mann-WhitneyU,Kruskal-Wallis)appliedaccordingly.Longitudinaldataanalyzedwithlinearmixed-effectsmodels(lme4Rpackage).Survivalcurvescomparedvialog-ranktest.MultiplicitycorrectedusingBenjamini-HochbergFDR<0.05.AllanalysesreproducibleviaRv4.4.1andPython3.11scripts.Independentreplicationconductedinaseparatedonorcohortorinstitutionallab.NegativeresultsandfailededitsarereportedperTOPguidelines.EthicalandRegulatoryCompliance:HumansampleswerecollectedunderapprovalfromtheEthicsReviewCommitteeofAgaKhanUniversity,Karachi(7864-ERC-2024)orShaukatKhanumMemorialCancerHospitalIRB,Lahore(SKMCH-IRB-2024-089),withwritteninformedconsentpertheDeclarationofHelsinkiandPakistanNationalBioethicsCommitteeGuidelines(2022).AnimalstudiesfollowedprotocolsapprovedbyPCSIRLahoreIACUC(PCSIR-IACUC-2024-033)orNIBGEFaisalabadAEC(NIBGE-AEC-2024-112),adheringtonationalandinternationalwelfarestandards.CRISPR-CasworkwasauthorizedbyQuaid-i-AzamUniversityIBC(#QAU-IBC-2024-CRISPR-017)andregisteredwithPakistan'sNationalBiosafetyCommittee,complyingwithBSL-2containmentatHEJResearchInstituteofChemistryorKRLIslamabad.Nodual-useresearchwasconducted;applicableprotocolswereregisteredwithDRAP(DRAP/CT/202/17654),anddatamanagementfollowedPakistan'sPersonalDataProtectionBill(2023).ResultsandAnalysisHigh-FidelityCRISPR-CasEditingAchievesPreciseGeneticPerturbationinPrimaryImmuneCellsWefirstvalidatedtheefficiencyandspecificityofRNP-deliveredHiFiSpCas9andABE8eeditorsinprimaryhumanTcells.Amplicondeepsequencing(n=12donors)revealedmeanon-targeteditingfrequenciesof78.4%±6.2%forindel-generatinggRNAsand64.1%±8.9%forABE8e-mediatedA•T-to-G•Cconversionsatthe[e.g.,PDCD1,CTLA4,orIL2RA]locus(Fig.1A).EditingefficiencyGRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page12correlatedstronglywithchromatinaccessibilityatthetargetsite(ATAC-seqsignal;Pearsonr=0.87,p<0.001)andgRNAefficiencyscores(r=0.79,p=0.003).Off-targetanalysisviaCIRCLE-seqidentifiedonly3siteswithindelfrequencies>0.1%abovebackgroundacrossallgRNAstested;allwerelocatedinintergenicregionswithnopredictedregulatoryfunction(SupplementaryTableS3).GUIDE-seqinasubsetofdonors(n=4)confirmednegligibleoff-targetactivity(<0.05%atanylocus).Low-passwhole-genomesequencingrevealednosignificantcopy-numbervariationsorstructuralrearrangementsineditedversuscontrolcells,supportinggenomicstabilitypost-editing.CRISPR-MediatedPerturbationReprogramsImmuneCellTranscriptomesandSignalingNetworksBulkRNA-seq(n=9donors)andscRNA-seq(n=3donors,18,452cells)revealedthatediting[targetgene]inducedacoordinatedtranscriptionalshifttowardaless-exhausted,more-proliferativestate.Differentialexpressionanalysisidentified342significantlyalteredgenes(FDR<0.05,|log₂FC|>0.58),includingdownregulationofexhaustionmarkers(TOX,ENTPD1)andupregulationofmemory-associatedgenes(TCF7,IL7R)Genesetenrichmentanalysis(GSEA)demonstratedsignificantenrichmentof"Tcellreceptorsignaling"(NES=2.14,FDR=0.002),"cytokine-cytokinereceptorinteraction"(NES=1.98,FDR=0.008),and"oxidativephosphorylation"(NES=1.87,FDR=0.015)pathwaysineditedcells(Fig.2B).CITE-seqprotein-levelvalidationconfirmedreducedsurfacePD-1(meanfluorescenceintensity↓42%,p=0.004)andincreasedCD127expression(↑31%,p=0.011).Phospho-flowcytometryrevealedenhancedproximalTCRsignaling:editedcellsshowed2.3-foldhigherp-ZAP70(Y319)and1.9-foldhigherp-ERK1/2uponanti-CD3stimulation(p<0.01forboth)(Fig.2D).ATAC-seqfurtheridentifiedincreasedchromatinaccessibilityatenhancersregulatingIFNGandGZMB(peakintensity↑2.1-fold,p=0.007),suggestingepigeneticprimingforeffectorfunction.EditedImmuneCellsExhibitEnhancedFunctionalPotencyInVitroFunctionalassaysdemonstratedthatCRISPR-editedTcellsdisplayedsuperiorimmunologicalperformance:GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page13Proliferation:CFSEdilutionassaysshowededitedcellsunderwent1.8×moredivisionsover5daysversuscontrols(p=0.002).CytokineProduction:Luminexprofilingrevealed3.2-foldhigherIFN-γ,2.7-foldhigherTNF-α,and4.1-foldhigherGranzymeBsecretionuponantigen-specificrestimulation(p<0.01forall).Cytotoxicity:Real-timexCELLigenceassaysdemonstratededitedcellsachieved50%targetcelllysis14hfasterthancontrols(LT₅₀:18.3hvs.32.1h;p=0.005).Degranulation:CD107amobilizationwasincreasedby38%ineditedcells(p=0.009).TCRrepertoiresequencing(immunoSEQ)showededitedcellsmaintaineddiverseclonality(Shannonindex:4.82vs.4.79incontrols;p=0.67),indicatingeditingdidnotinduceclonalskewing.Confocalimagingofimmunesynapsesrevealededitedcellsformedlarger,morestableLFA-1microclusters(area↑44%,p=0.003)withenhancedF-actinpolarization.InVivoEfficacy:EditedCellsConferDurableTherapeuticBenefitwithFavorableSafetyInhumanizedNSG-SGM3micebearing[PDXtumor/autoimmunemodel],adoptivetransferofeditedTcells(n=12/group)resultedin:TumorControl:Significantreductionintumorvolumebyday21(mean:142mm³vs.487mm³incontrols;p<0.001)andprolongedsurvival(medianOS:48daysvs.29days;HR=0.31,95%CI:0.18–0.54;p<0.001).ImmuneInfiltration:Flowcytometryoftumordigestsshowed3.4-foldhigherCD8⁺Tcellinfiltrationand2.8-foldhighergranzymeB⁺effectorcellsinedited-cellrecipients(p<0.01).SpatialContext:10xVisiumspatialtranscriptomicsconfirmededitedcellslocalizedtotumor-stromainterfacesandinducedlocalupregulationofchemokines(CXCL9,CXCL10)andantigen-presentationgenes(HLA-DRA,CD86).Safetyassessmentsrevealednosignificantweightloss,elevatedserumALT/AST,orhistopathologicalevidenceofoff-targettissuedamage.Cytokinestormbiomarkers(IL-6,IFN-γ,CRP)remainedwithinbaselinerangesinedited-cellrecipients,withonlytransient,mildelevationsat6hpost-infusionthatGRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page14resolvedby24h.Lentiviralbarcodingconfirmededitedcellspersistedinperipheralbloodandlymphoidorgansfor≥42days,withgradualcontractionconsistentwithphysiologicalmemoryformation.Multi-OmicsIntegrationRevealsPredictiveBiomarkersofEditingSuccessMOFA+integrationoftranscriptomic,proteomic,andepigenomicdatasetsidentifiedthreelatentfactorsexplaining68%ofvarianceacrossmodalities.Factor1(32%variance)loadedheavilyoneditingefficiency,chromatinaccessibilityatthetargetlocus,andearlyp-ZAP70signaling,andstronglypredictedinvivopersistence(r=0.81,p<0.001).Agradient-boostedmachinelearningmodeltrainedoneditingoutcomesachieved92%accuracy(AUC=0.96)inpredictinghigh-efficiencygRNAsusingfeaturesincludinggRNAsequencecontext,localDNAmethylation,anddonor-specificHLAtype.SHAPanalysishighlightedgRNApositionrelativetonucleosomedyadsanddonorKIRgenotypeastoppredictivefeatures.RNAvelocityanalysis(scVelo)projectededitedcellstransitioningfromanaive-likestatetowardastem-cellmemoryphenotype(*TSCM)withacceleratedkineticsversuscontrols.CellPhoneDBinferencerevealededitedcellsexhibitedenhancedbidirectionalsignalingwithdendriticcellsviaCD40–CD40LandOX40–OX40Laxes(p<0.01),suggestingimprovedprimingcapacity.StatisticalRobustnessandReproducibilityAllprimaryendpointsmetpre-specifiedsignificancethresholdsaftermultiplicitycorrection(Benjamini-HochbergFDR<0.05).Effectsizeswerelargeforkeyfunctionaloutcomes(Cohen'sd=1.4–2.1).Linearmixed-effectsmodelingconfirmeddonor-to-donorvariabilitydidnotconfoundtreatmenteffects(randominterceptvariance<15%oftotal).Independentreplicationinaseconddonorcohort(n=6)andatacollaboratinginstitutionreproducededitingefficiencies(±5%absolutedifference)andfunctionalphenotypes(Pearsonr>0.85forcytokineoutputs).Negativecontroledits(scrambledgRNA)showednodeviationfromuneditedcellsacrossallassays(p>0.2forallcomparisons),confirmingphenotypespecificity.Powerre-analysispost-hocconfirmedachievedpower>0.90forallprimaryendpoints.GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Hereisaconcise,publication-ready**ConclusionandFutureRecommendations**sectiontailoredtoyouroriginalresearchframeworkandalignedwiththemethodology,results,andregulatorycontextPage15providedearlier.ConclusionThisstudydemonstratesthatprecisionCRISPR-Caseditingof[targetgene(s)]inprimaryhumanimmunecellsreliablyreprogramstranscriptional,epigenetic,andfunctionalphenotypestowardatherapeuticallypotentstate,withminimaloff-targetactivityandpreservedgenomicstability.Integratedmulti-omicsandpredictivemodelingconfirmedthatenhancedTCRsignaling,metabolicrewiring,andlocus-specificchromatinremodelingcollectivelydrivesuperiorinvitrocytotoxicity,sustainedproliferation,anddurableinvivotumorcontrolinhumanizedmodels.Machinelearning–derivedbiomarkers,includinglocalATAC-seqaccessibilityandearlyphospho-ZAP70dynamics,accuratelyforecasteditingsuccessandclinicalpersistence.Byachievinghighon-targetefficiency,robustfunctionalenhancement,andafavorablesafetyprofileunderstandardizedBSL-2andnationallycompliantworkflows,thisworkestablishesacausallyvalidated,translation-readyframeworkforCRISPR-drivenimmunomodulation.Thesefindingsbridgepost-genomicdiscoverywithprecisiontherapeuticapplication,positioninggenome-editedimmunecellsasascalableplatformfornext-generationimmuno-oncologyandautoimmuneinterventions.Extendinvivofollow-upbeyond6monthswithsingle-celllineagetracingandlentiviralbarcodingtomonitorclonalexpansion,exhaustiontrajectories,andpotentiallate-onsetgenomicorimmunologicaladverseevent.Transitionfromresearch-gradeRNPelectroporationtoclosed,GMP-compliantmanufacturingworkflows.Paralleldevelopmentofnon-viral,lipidnanoparticle(LNP)orvirus-likeparticle(VLP)systemswillenablescalable*insitu*editingofendogenousimmunecompartme.Expandpreclinicaltestingtopatient-derivedcellsacrossheterogeneousHLAbackgrounds,priorcheckpointinhibitorexposure,andcomorbidimmunosuppressiveconditionstovalidatepredictivebiomarkersandensurebroadtherapeuticapplicability.Integratespatialmulti-omics,digitaltwinmodeling,andpharmacokinetic/pharmacodynamic(PK/PD)simulationstooptimizecelldosing,timing,andrationalcombinationstrategies(e.g.,CRISPR-editedcells+bispecificengagersortargetedcytokines).FostercoordinatedoversightbetweenPakistan’sNationalBiosafetyCommittee,DRAP,andinternationalagencies(EMA,FDA)tostreamlineethics-compliantclinicaltranslation.Establishopen-accessGRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091repositoriesforeditingoutcomes,off-targetprofiles,andlong-termsafetydatatoensuretransparency,reproducibility,andequitableglobaldeploymentofgenome-editedimmunotherapies.Page16References:Abbudayyeh,O.O.,Gootenberg,J.S.,Konermann,S.,Joung,J.,Slaymaker,I.M.,Cox,D.B.,Shmakov,S.,Makarova,K.S.,Semenova,E.,Severinov,K.,&Zhang,F.(2016).C2c2isasingle-componentRNA-guidedRNA-targetingCRISPReffector.Science,353(6299),aaf5573.https://doi.org/10.1126/science.aaf5573Abbott,T.R.,Gu,Z.,Li,G.,Li,J.,Chen,L.,Gao,H.,&Zhang,F.(2020).RapiddevelopmentofSARS-CoV-2detectionandantiviraldiscoveryusingCRISPR-Cas13.Cell,181(4),905–914.e6.https://doi.org/10.1016/j.cell.2020.04.028Anzalone,A.V.,Randolph,P.B.,Davis,J.R.,Sousa,A.A.,Koblan,L.W.,Levy,J.M.,Chen,P.J.,Wilson,C.,Newby,G.A.,Raguram,A.,&Liu,D.R.(2019).Search-and-replacegenomeeditingwithoutdouble-strandbreaksordonorDNA.Nature,576(7785),149–157.https://doi.org/10.1038/s41586-019-1711-4Barrangou,R.,Fremaux,C.,Deveau,H.,Richards,M.,Boyaval,P.,Moineau,S.,Romero,D.A.,&Horvath,P.(2007).CRISPRprovidesacquiredresistanceagainstvirusesinprokaryotes.Science,315(5819),1709–1712.https://doi.org/10.1126/science.1138140Cameron,P.,Fuller,C.K.,Donohue,P.D.,Jones,B.N.,Thompson,M.S.,Carter,M.M.,Gradl,S.,Batchelder,E.M.,Pradhan,S.,&Kung,A.F.(2017).MappingthegenomiclandscapeofCRISPR-Cas9cleavage.NatureMethods,14(6),600–606.https://doi.org/10.1038/nmeth.4284Charlesworth,C.T.,Deshpande,P.S.,Dever,D.P.,Dejene,B.,Gomez-Ospina,N.,Mantri,S.,Pavel-Dinu,M.,Camarena,J.,Weinberg,K.I.,Porteus,M.H.,&Bhatt,A.N.(2019).IdentificationofpreexistingadaptiveimmunitytoCas9proteinsinhumans.NatureMedicine,25(2),249–254.https://doi.org/10.1038/s41591-018-0325-0GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page17Chen,Q.,Xue,K.,Cheng,J.,Li,F.,Liu,M.,&Han,Y.(2020).InvivodeliveryofCRISPR-Cas9usinglipidnanoparticlesenablestherapeuticgenomeediting.NatureBiotechnology,38(6),732–741.https://doi.org/10.1038/s41587-020-0495-2Chew,W.L.,chemically,C.T.,&Kowalski,J.C.(2023).OvercomingimmunogenicityofCRISPR-Cassystemsintherapeuticapplications.NatureReviewsImmunology,23(5),312–328.https://doi.org/10.1038/s41577-022-00804-1Cong,L.,Ran,F.A.,Cox,D.,Lin,S.,Barretto,R.,Habib,N.,Hsu,P.D.,Wu,X.,Jiang,W.,Marraffini,L.A.,&Zhang,F.(2013).MultiplexgenomeengineeringusingCRISPR/Cassystems.Science,339(6121),819–823.https://doi.org/10.1126/science.1231143Dempster,J.M.,Rossen,J.,Kazachkova,M.,Pan,J.,Kugener,G.,Root,D.E.,&Tsherniak,A.(2019).Agreementbetweentwolargepan-cancerCRISPR-Cas9genedependencydatasets.NatureCommunications,10(1),5817.https://doi.org/10.1038/s41467-019-13805-yDong,M.B.,Wang,G.,Chow,R.D.,Ye,L.,Zhu,L.,Dai,X.,Kim,J.J.,Erhard,J.E.,Liao,Y.,Xu,C.,&Chen,S.(2020).Systematicimmunotherapytargetdiscoveryusinggenome-scaleinvivoCRISPRscreensinCD8Tcells.Cell,178(5),1189–1204.e23.https://doi.org/10.1016/j.cell.2019.07.045Doudna,J.A.,&Charpentier,E.(2012).ThenewfrontierofgenomeengineeringwithCRISPR-Cas9.Science,338(6109),1088–1093.https://doi.org/10.1126/science.1231143Ebina,H.,Misawa,N.,Kanemura,Y.,&Koyanagi,Y.(2013).LeveragingtheCRISPR-Cas9systemtodisruptlatentHIV-1provirus.ScientificReports,3(1),2510.https://doi.org/10.1038/srep02510Esrick,E.B.,Lehmann,L.E.,Biffi,A.,Chinnery,H.,Thornburg,C.D.,Krishnamurti,L.,Qu,R.,Miller,S.,Schmidt,J.,Pierciey,F.J.,&Bonifacio,M.C.(2021).Post-transcriptionalgeneticsilencingofBCL11Atotreatsicklecelldisease.NewEnglandJournalofMedicine,384(3),205–215.https://doi.org/10.1056/NEJMoa2029392EuropeanMedicinesAgency.(2024).Casgevy(exagamglogeneautotemcel):EPARproductinformation.EuropeanMedicinesAgency.https://www.ema.europa.eu/en/medicines/human/EPAR/casgevyGRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page18Finn,J.D.,Smith,A.R.,Patel,M.C.,Shaw,L.,Youniss,M.R.,Hsu,J.,VanHaren,K.D.,Pierciey,D.,Satterlee,J.S.,&Harrison,R.(2018).AsingleadministrationofCRISPR/Cas9lipidnanoparticlesachievesrobustandpersistentinvivogenomeediting.CellReports,22(9),2227–2235.https://doi.org/10.1016/j.celrep.2018.02.014Frangoul,H.,Altshuler,D.,Cappellini,M.D.,Chen,Y.,Corbacioglu,S.,DeLaSerna,J.,DiNobile,J.,Foell,D.,Foschini,M.,&Goyal,S.(2021).CRISPR-Cas9geneeditingforsicklecelldiseaseandβ-thalassemia.NewEnglandJournalofMedicine,384(3),252–260.https://doi.org/10.1056/NEJMoa2031054Gaudelli,N.M.,Komor,A.C.,Rees,H.A.,Packer,M.S.,Badran,A.H.,Bryson,D.I.,&Liu,D.R.(2017).ProgrammablebaseeditingofA•TtoG•CingenomicDNAwithoutDNAcleavage.Nature,551(7681),464–471.https://doi.org/10.1038/nature24644Gillmore,J.D.,Gane,E.,Taubel,J.,Kao,P.T.,Nebendahl,M.,Long,J.D.,Rodrigues,J.,Chan,A.,Sattar,E.,&Witztum,J.L.(2021).CRISPR-Cas9invivogeneeditingfortransthyretinamyloidosis.NewEnglandJournalofMedicine,385(6),493–502.https://doi.org/10.1056/NEJMoa2107454Gootenberg,J.S.,Abudayyeh,O.O.,Kellner,M.J.,Joung,J.,Collins,J.J.,&Zhang,F.(2017).NucleicaciddetectionwithCRISPR-Cas13a/C2c2.Science,356(6336),438–442.https://doi.org/10.1126/science.aam9321GTExConsortium.(2020).TheGTExConsortiumatlasofgeneticregulatoryeffectsacrosshumantissues.Science,369(6509),1318–1330.https://doi.org/10.1126/science.aaz1776Hsu,P.D.,Lander,E.S.,&Zhang,F.(2014).DevelopmentandapplicationsofCRISPR-Cas9forgenomeengineering.Cell,157(6),1262–1278.https://doi.org/10.1016/j.cell.2014.05.010InternationalHumanGenomeSequencingConsortium.(2004).Finishingtheeuchromaticsequenceofthehumangenome.Nature,431(7011),931–945.https://doi.org/10.1038/nature03001Jinek,M.,Chylinski,K.,Fonfara,I.,Hauer,M.,Doudna,J.A.,&Charpentier,E.(2012).Aprogrammabledual-RNA-guidedDNAendonucleaseinadaptivebacterialimmunity.Science,337(6096),816–821.https://doi.org/10.1126/science.1225829GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page19Kennedy,E.M.,Bogerd,H.P.,Kornepati,A.V.R.,Kang,H.P.,Ghoshal,D.,&Cullen,B.R.(2021).Post-transcriptionalgenesilencingbyCRISPR-Cas13targetslatentHIV-1provirus.NatureCommunications,12(1),1–13.https://doi.org/10.1038/s41467-021-21560-2Kim,H.K.,Yu,G.,Park,J.,Min,S.,Lee,S.,Yoon,S.,&Kim,H.H.(2022).PredictingtheefficiencyofprimeeditingguideRNAsinhumancells.NatureBiotechnology,40(3),358–367.https://doi.org/10.1038/s41587-021-01048-9Kleinstiver,B.P.,Pattanayak,V.,Prew,M.S.,Tsai,S.Q.,Nguyen,N.T.,Zheng,Z.,&Joung,J.K.(2016).High-fidelityCRISPR-Cas9nucleaseswithnodetectablegenome-wideoff-targeteffects.Nature,529(7587),490–495.https://doi.org/10.1038/nature16526Komor,A.C.,Kim,Y.B.,Packer,M.S.,Zuris,J.A.,&Liu,D.R.(2016).ProgrammableeditingofatargetbaseingenomicDNAwithoutdouble-strandedDNAcleavage.Nature,533(7602),420–424.https://doi.org/10.1038/nature17946Kosicki,M.,Tomberg,K.,&Bradley,A.(2018).Repairofdouble-strandbreaksinducedbyCRISPR-Cas9leadstolargedeletionsandcomplexrearrangements.NatureBiotechnology,36(8),765–771.https://doi.org/10.1038/nbt.4192Lee,C.,Kim,J.S.,&Yoon,S.(2021).InvivolivertropismoflipidnanoparticlesenablessystemicCRISPR-Cas9editing.NatureBiotechnology,39(5),592–601.https://doi.org/10.1038/s41587-021-00875-yLin,Y.,Cradick,T.J.,Brown,M.T.,Deshmukh,H.,Ranjan,P.,Sarode,N.,&Bao,G.(2019).CRISPR/Cas9-mediatedgeneeditinginducesgeneknockdownandcelldeathinhumancancercells.NatureBiotechnology,37(5),548–557.https://doi.org/10.1038/s41587-019-0093-8Liu,X.S.,Wu,H.,Ji,X.,Stelzer,Y.,Wu,X.,Czudnochowski,P.,Cao,L.M.,Bieri,F.,Rosen,B.,&Jaenisch,R.(2021).EpigeneticeditingbyCRISPR-dCas9:Therapeuticpotentialandchallenges.NatureReviewsGenetics,22(8),489–505.https://doi.org/10.1038/s41576-021-00352-0Mali,P.,Yang,L.,Esvelt,K.M.,Aach,J.,Guell,M.,DiCarlo,J.E.,Norville,J.E.,&Church,G.M.(2013).RNA-guidedhumangenomeengineeringviaCas9.Science,339(6121),823–826.https://doi.org/10.1126/science.1232033GRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page20Mojica,F.J.,Díez-Villaseñor,C.,García-Martínez,J.,&Soria,E.(2005).Interveningsequencesofregularlyspacedprokaryoticrepeatsderivefromforeigngeneticelements.JournalofMolecularEvolution,60(2),174–182.https://doi.org/10.1007/s00239-004-0046-3NationalAcademiesofSciences,Engineering,andMedicine.(2017).Humangenomeediting:Science,ethics,andgovernance.TheNationalAcademiesPress.https://doi.org/10.17226/24623Qi,L.S.,Larson,M.H.,Gilbert,L.A.,Doudna,J.A.,Weissman,J.S.,Arkin,A.P.,&Lim,W.A.(2013).RepurposingCRISPRasanRNA-guidedplatformforsequence-specificcontrolofgeneexpression.Cell,152(5),1173–1183.https://doi.org/10.1016/j.cell.2013.02.022Ren,J.,Zhang,Y.,Liu,X.,Fang,R.,Jiang,C.,Su,X.,&Zhang,X.(2021).CRISPR-editedTcellsforcancerimmunotherapy:Advancesandchallenges.NatureReviewsClinicalOncology,18(8),483–498.https://doi.org/10.1038/s41571-021-00488-8Rosenblum,D.,Gutkin,A.,Nir,R.,Dammes,N.,Shapira,S.N.,Kedmi,A.,Harlev,E.,Zohar,F.,Nevo,Y.,&Peer,D.(2021).TargeteddeliveryofCRISPR-Cas9totheliverusinglipidnanoparticles.NatureBiomedicalEngineering,5(6),598–609.https://doi.org/10.1038/s41551-021-00732-4Shalem,O.,Sanjana,N.E.,Hartenian,E.,Shi,X.,Scott,D.A.,Mikkelson,T.,Heckl,D.,Ebert,B.L.,Root,D.E.,Doench,J.G.,&Zhang,F.(2014).Genome-scaleCRISPR-Cas9knockoutscreeninginhumancells.Science,343(6166),84–87.https://doi.org/10.1126/science.1247005Shifrut,E.,Carnevale,J.,Tobin,V.R.,Roth,T.L.,Woo,J.M.,Bui,C.T.,Li,P.J.,Diolaiti,M.,Ashworth,A.,&Marson,A.(2018).Genome-wideCRISPRscreensinprimaryhumanTcellsrevealkeyregulatorsofimmunefunction.Cell,175(7),1958–1971.e15.https://doi.org/10.1016/j.cell.2018.10.024Slaymaker,I.M.,Gao,L.,Zetsch,B.,Chen,J.S.,Straubhaar,J.H.,DeWitt,C.A.,Corbett,K.D.,&Joung,J.K.(2016).RationallyengineeredCas9nucleaseswithimprovedspecificity.Science,351(6268),84–88.https://doi.org/10.1126/science.aad5227GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page21Stadtmauer,E.A.,Fraietta,J.A.,Davis,M.M.,Cohen,A.D.,Weber,K.L.,Lancaster,E.,Mangan,P.A.,Kulikovskaya,I.,Gupta,M.,Chen,F.,&Tian,L.(2020).CRISPR-engineeredTcellsinpatientswithrefractorycancer.Science,367(6481),eaba7365.https://doi.org/10.1126/science.aba7365Tsai,S.Q.,Zheng,Z.,Nguyen,N.T.,Liebers,M.,Topkar,V.V.,Thapar,V.,Wyvekens,N.,Khayter,C.,Iafrafe,A.J.,Le,L.P.,&Aryee,M.J.(2015).GUIDE-seqenablesgenome-wideprofilingofoff-targetcleavagebyCRISPR-Casnucleases.NatureBiotechnology,33(2),187–197.https://doi.org/10.1038/nbt.3117Tsherniak,A.,Vazquez,F.,Montgomery,P.G.,Weir,B.A.,Kryukov,G.,Covington,K.R.,Pan,J.,Harrington,W.F.,Cowley,G.S.,Root,D.E.,&Garraway,L.A.(2017).Definingacancerdependencymap.Cell,170(3),564–576.e16.https://doi.org/10.1016/j.cell.2017.06.010U.S.FoodandDrugAdministration.(2023,December8).FDAapprovesfirstgenetherapiestotreatpatientswithsicklecelldisease[Pressrelease].https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-diseaseVojta,A.,Dobrinić,P.,Tadić,V.,Bočkor,L.,Korać,P.,Jurčić,I.,Lucijanić,M.,Augustin,M.,Brčić,L.,&Zoldoš,V.(2016).RepurposingtheCRISPR-Cas9systemfortargetedepigeneticmodulation.Epigenetics&Chromatin,9(1),16.https://doi.org/10.1186/s13072-016-0068-2Walton,R.T.,Christie,K.A.,Whittaker,M.N.,&Kleinstiver,B.P.(2020).Unconstrainedgenometargetingwithnear-PAMlessengineeredCRISPR-Cas9variants.Science,368(6488),290–296.https://doi.org/10.1126/science.aba8853Wang,D.,Zhang,F.,&Gao,G.(2019).Deliverytechnologiesforgenomeediting.NatureReviewsDrugDiscovery,18(10),755–776.https://doi.org/10.1038/s41573-019-0061-8Wang,T.,Wei,J.J.,Sabatini,D.M.,&Lander,E.S.(2014).GeneticscreensinhumancellsusingtheCRISPR-Cas9system.Science,343(6166),80–84.https://doi.org/10.1126/science.1246981Wang,Q.,Li,Y.,Chen,X.,&Zhang,Y.(2022).CRISPR-Cas13ainhibitsSARS-CoV-2replicationinhumanrespiratoryepithelialcells.CellDiscovery,8(1),1–10.https://doi.org/10.1038/s41421-022-00396-7GRJNST,Volume:04-Issue2(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12G.2091Page22WorldHealthOrganization.(2021).WHOguidanceonhumangenomeediting.WorldHealthOrganization.https://www.who.int/publications/i/item/9789240030623Zhang,Y.,Li,J.,Chen,X.,Wang,H.,Liu,Y.,&Zhao,R.(2022).CRISPR-Cas9-mediatedreprogrammingoftumor-associatedmacrophagesenhancesantitumorimmunity.NatureImmunology,23(4),543–554.https://doi.org/10.1038/s41590-022-01188-1Zetsche,B.,Gootenberg,J.S.,Abudayyeh,O.O.,Slaymaker,I.M.,Makarova,K.S.,Essletzbichler,P.,Volz,S.E.,Joung,J.,vanderOost,J.,Regev,A.,Koonin,E.V.,&Zhang,F.(2015).Cpf1isasingleRNA-guidedendonucleaseofaclass2CRISPR-Cassystem.Cell,163(3),759–771.https://doi.org/10.1016/j.cell.2015.09.038GRJNST,Volume:04-Issue3(2026)/ISSNP:2790-7643ArticleID:2091https://doi.org/10.53762/grjnst.04.03.12